{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-075932","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.669876+00:00","generated_at":"2026-06-04T08:37:08.425299+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dyne Therapeutics appoints John Cox as President and CEO, succeeding Joshua Brumm","bullets":["John Cox appointed President and CEO effective March 25, 2024; also elected Class I director.","Joshua Brumm resigns as CEO and from the Board; will serve as consultant for 12 months.","Cox receives $700K base salary, up to 60% annual bonus, and option for 679,853 shares.","Brumm gets separation: 12 months salary, COBRA, and partial equity acceleration.","Board adopts 2024 Inducement Equity Plan authorizing 900,000 shares for new hires."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-075932","json":"https://secwatch.observer/filing/0001193125-24-075932.json","markdown":"https://secwatch.observer/filing/0001193125-24-075932.md","text":"https://secwatch.observer/filing/0001193125-24-075932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/d93072d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:37:08.425299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38e667b5b2","claim":"Joshua Brumm departed as Chief Executive Officer at Dyne Therapeutics, Inc..","evidence_excerpt":"succeeding Joshua Brumm","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"de11f4025b","claim":"John Cox was elected as Class I Director at Dyne Therapeutics, Inc..","evidence_excerpt":"Mr. Cox was elected as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"de24e95bb4","claim":"John Cox was appointed as President and Chief Executive Officer at Dyne Therapeutics, Inc..","evidence_excerpt":"had appointed John Cox as President and Chief Executive Officer of the Company succeeding Joshua Brumm","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524075932/0001193125-24-075932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}